An engineered ultrahigh affinity bi-paratopic uPAR targeting agent confers enhanced tumor targeting.

Autor: Cherf GM; Department of Bioengineering, Stanford University, Stanford, California, USA., Lee RB; Department of Bioengineering, Stanford University, Stanford, California, USA.; Department of Chemical Engineering, Stanford University, Stanford, California, USA., Mehta N; Department of Bioengineering, Stanford University, Stanford, California, USA., Clifford C; Department of Bioengineering, Stanford University, Stanford, California, USA., Torres K; Department of Bioengineering, Stanford University, Stanford, California, USA., Kintzing JR; Department of Bioengineering, Stanford University, Stanford, California, USA., Cochran JR; Department of Bioengineering, Stanford University, Stanford, California, USA.; Department of Chemical Engineering, Stanford University, Stanford, California, USA.; Stanford Cancer Institute, Stanford University, Stanford, California, USA.

Publikováno v: Biotechnology and bioengineering [Biotechnol Bioeng] 2024 Oct; Vol. 121 (10), pp. 3169-3180. Date of Electronic Publication: 2024 Jul 04.

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8.

Autor: Roy A; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Shi L; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.; Encodia Inc, 5785 Oberlin Drive, San Diego, CA, 92121, USA., Chang A; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, USA., Dong X; Program in Cellular and Molecular Medicine, Children's Hospital Boston, and Departments of Biological Chemistry and Molecular Pharmacology and of Medicine, Harvard Medical School, Boston, MA, USA.; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.; Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, Nanjing, China., Fernandez A; Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., Kraft JC; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Li J; Program in Cellular and Molecular Medicine, Children's Hospital Boston, and Departments of Biological Chemistry and Molecular Pharmacology and of Medicine, Harvard Medical School, Boston, MA, USA., Le VQ; Program in Cellular and Molecular Medicine, Children's Hospital Boston, and Departments of Biological Chemistry and Molecular Pharmacology and of Medicine, Harvard Medical School, Boston, MA, USA., Winegar RV; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, USA., Cherf GM; Department of Bioengineering, Stanford University, Stanford, CA, 94305, USA.; Denali Therapeutics, South San Francisco, CA, USA., Slocum D; Program in Cellular and Molecular Medicine, Children's Hospital Boston, and Departments of Biological Chemistry and Molecular Pharmacology and of Medicine, Harvard Medical School, Boston, MA, USA., Poulson PD; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, USA., Casper GE; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, USA., Vallecillo-Zúniga ML; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, USA., Valdoz JC; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, USA., Miranda MC; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden., Bai H; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Kipnis Y; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, 98195, USA., Olshefsky A; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.; Department of Bioengineering, University of Washington, Seattle, WA, 98195, USA., Priya T; Department of Materials Science and Engineering, University of Washington, Seattle, WA, 98195, USA.; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA., Carter L; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Ravichandran R; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Chow CM; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Johnson MR; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Cheng S; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Smith M; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Overed-Sayer C; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Finch DK; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Alchemab Therapeutics Ltd, Cambridge, UK., Lowe D; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Evox Therapeutics Limited, Oxford Science Park, Medawar Centre, East Building, Robert Robinson Avenue, Oxford, OX4 4HG, England., Bera AK; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Matute-Bello G; Center for Lung Biology, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, USA., Birkland TP; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA., DiMaio F; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Raghu G; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.; Dept of Medicine, University of Washington, Seattle, WA, USA., Cochran JR; Department of Bioengineering, Stanford University, Stanford, CA, 94305, USA., Stewart LJ; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA., Campbell MG; Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA. melody@fredhutch.org., Van Ry PM; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, USA. pvanry@byu.edu., Springer T; Program in Cellular and Molecular Medicine, Children's Hospital Boston, and Departments of Biological Chemistry and Molecular Pharmacology and of Medicine, Harvard Medical School, Boston, MA, USA. springer@crystal.harvard.edu., Baker D; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA. dabaker@uw.edu.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, 98195, USA. dabaker@uw.edu.

Publikováno v: Nature communications [Nat Commun] 2023 Sep 13; Vol. 14 (1), pp. 5660. Date of Electronic Publication: 2023 Sep 13.

CD98hc is a target for brain delivery of biotherapeutics.

Autor: Chew KS; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Wells RC; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Moshkforoush A; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Chan D; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Lechtenberg KJ; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Tran HL; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Chow J; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Kim DJ; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Robles-Colmenares Y; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Srivastava DB; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Tong RK; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Tong M; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Xa K; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Yang A; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Zhou Y; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Akkapeddi P; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Annamalai L; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Bajc K; Department of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.; Department of Neurosciences, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA., Blanchette M; Department of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.; Department of Neurosciences, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA., Cherf GM; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Earr TK; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Gill A; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Huynh D; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Joy D; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Knight KN; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Lac D; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Leung AW; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Lexa KW; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Liau NPD; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Becerra I; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Malfavon M; Department of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.; Department of Neurosciences, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA., McInnes J; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Nguyen HN; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Lozano EI; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Pizzo ME; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Roche E; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Sacayon P; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Calvert MEK; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Daneman R; Department of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.; Department of Neurosciences, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA., Dennis MS; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Duque J; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Gadkar K; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Lewcock JW; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Mahon CS; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Meisner R; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Solanoy H; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Thorne RG; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.; Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA., Watts RJ; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Zuchero YJY; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. zuchero@dnli.com., Kariolis MS; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. kariolis@dnli.com.

Publikováno v: Nature communications [Nat Commun] 2023 Aug 19; Vol. 14 (1), pp. 5053. Date of Electronic Publication: 2023 Aug 19.

Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic.

Autor: Logan T; Denali Therapeutics, South San Francisco, CA, USA., Simon MJ; Denali Therapeutics, South San Francisco, CA, USA., Rana A; Denali Therapeutics, South San Francisco, CA, USA., Cherf GM; Denali Therapeutics, South San Francisco, CA, USA., Srivastava A; Denali Therapeutics, South San Francisco, CA, USA., Davis SS; Denali Therapeutics, South San Francisco, CA, USA., Low RLY; Denali Therapeutics, South San Francisco, CA, USA., Chiu CL; Denali Therapeutics, South San Francisco, CA, USA., Fang M; Denali Therapeutics, South San Francisco, CA, USA., Huang F; Denali Therapeutics, South San Francisco, CA, USA., Bhalla A; Denali Therapeutics, South San Francisco, CA, USA., Llapashtica C; Denali Therapeutics, South San Francisco, CA, USA., Prorok R; Denali Therapeutics, South San Francisco, CA, USA., Pizzo ME; Denali Therapeutics, South San Francisco, CA, USA., Calvert MEK; Denali Therapeutics, South San Francisco, CA, USA., Sun EW; Denali Therapeutics, South San Francisco, CA, USA., Hsiao-Nakamoto J; Denali Therapeutics, South San Francisco, CA, USA., Rajendra Y; Denali Therapeutics, South San Francisco, CA, USA., Lexa KW; Denali Therapeutics, South San Francisco, CA, USA., Srivastava DB; Denali Therapeutics, South San Francisco, CA, USA., van Lengerich B; Denali Therapeutics, South San Francisco, CA, USA., Wang J; Denali Therapeutics, South San Francisco, CA, USA., Robles-Colmenares Y; Denali Therapeutics, South San Francisco, CA, USA., Kim DJ; Denali Therapeutics, South San Francisco, CA, USA., Duque J; Denali Therapeutics, South San Francisco, CA, USA., Lenser M; Denali Therapeutics, South San Francisco, CA, USA., Earr TK; Denali Therapeutics, South San Francisco, CA, USA., Nguyen H; Denali Therapeutics, South San Francisco, CA, USA., Chau R; Denali Therapeutics, South San Francisco, CA, USA., Tsogtbaatar B; Denali Therapeutics, South San Francisco, CA, USA., Ravi R; Denali Therapeutics, South San Francisco, CA, USA., Skuja LL; Denali Therapeutics, South San Francisco, CA, USA., Solanoy H; Denali Therapeutics, South San Francisco, CA, USA., Rosen HJ; Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; On behalf of the ALLFTD investigators., Boeve BF; On behalf of the ALLFTD investigators; Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN, USA., Boxer AL; Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; On behalf of the ALLFTD investigators., Heuer HW; Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; On behalf of the ALLFTD investigators., Dennis MS; Denali Therapeutics, South San Francisco, CA, USA., Kariolis MS; Denali Therapeutics, South San Francisco, CA, USA., Monroe KM; Denali Therapeutics, South San Francisco, CA, USA., Przybyla L; Denali Therapeutics, South San Francisco, CA, USA., Sanchez PE; Denali Therapeutics, South San Francisco, CA, USA., Meisner R; Denali Therapeutics, South San Francisco, CA, USA., Diaz D; Denali Therapeutics, South San Francisco, CA, USA., Henne KR; Denali Therapeutics, South San Francisco, CA, USA., Watts RJ; Denali Therapeutics, South San Francisco, CA, USA., Henry AG; Denali Therapeutics, South San Francisco, CA, USA., Gunasekaran K; Denali Therapeutics, South San Francisco, CA, USA., Astarita G; Denali Therapeutics, South San Francisco, CA, USA; Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA., Suh JH; Denali Therapeutics, South San Francisco, CA, USA., Lewcock JW; Denali Therapeutics, South San Francisco, CA, USA., DeVos SL; Denali Therapeutics, South San Francisco, CA, USA. Electronic address: devos@dnli.com., Di Paolo G; Denali Therapeutics, South San Francisco, CA, USA. Electronic address: dipaolo@dnli.com.

Publikováno v: Cell [Cell] 2021 Sep 02; Vol. 184 (18), pp. 4651-4668.e25. Date of Electronic Publication: 2021 Aug 26.

Applications of Yeast Surface Display for Protein Engineering.

Autor: Cherf GM; Department of Bioengineering, Stanford University, Stanford, CA, 94305, USA., Cochran JR

Publikováno v: Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2015; Vol. 1319, pp. 155-75.